CJC-1295 and ipamorelin are the most widely combined growth hormone secretagogue protocol in compounding and biohacking practice. They are prescribed together by functional medicine clinics, discussed in every peptide forum, and sold as a pair by research vendors. No published human clinical trial has ever tested the combination.
Each compound has been studied individually in humans. Both confirmed their GH-stimulating mechanisms work. Neither has demonstrated clinical efficacy for the outcomes that actually drive their use: body composition, anti-aging, sleep quality, or performance. This post examines what each compound brings to the stack, where the evidence stands for each, and what the honest assessment looks like for the combination.
The scientific case for combining CJC-1295 and ipamorelin is genuinely compelling. They stimulate growth hormone release through two independent receptor pathways that converge on the same pituitary cell.
CJC-1295 (also called Modified GRF 1-29, or mod-GRF) is a GHRH analogue. It activates the GHRH receptor on pituitary somatotroph cells, triggering intracellular cAMP-PKA signaling. Ipamorelin is a ghrelin mimetic. It activates the GHS-R1a receptor on the same somatotroph cells, triggering calcium-dependent signaling. These are distinct intracellular pathways that independently promote GH vesicle exocytosis.
When both pathways are activated simultaneously, the GH response is synergistic, not merely additive. Animal model data from Bowers et al. (1991-1999) consistently showed 2 to 3 fold amplification of GH release compared to either compound alone. This synergy is well-established in preclinical models. It has never been measured in a controlled human study.
CJC-1295 exists in two forms that are frequently confused. CJC-1295 with DAC (Drug Affinity Complex) has a half-life of 6 to 8 days and produces sustained baseline GH elevation. CJC-1295 without DAC (Modified GRF 1-29) has a half-life of approximately 30 minutes and produces discrete GH pulses. The without-DAC version is what gets combined with ipamorelin, because its short pulse profile aligns with ipamorelin's acute GH release rather than producing continuous elevation.
The Teichman 2006 Phase 1 RCT confirmed CJC-1295 with DAC's mechanism in humans: 2 to 10 fold GH elevation, 1.5 to 3 fold IGF-1 elevation, and preserved pulsatility in approximately 100 healthy adults. This is real human data confirming the mechanism works. But mechanism confirmation is not efficacy evidence. Elevating GH is not the same as demonstrating that the GH elevation produces a clinical benefit.
The trial that would have provided efficacy data was the Phase 2 HIV lipodystrophy study. It was permanently terminated after a patient death from myocardial infarction. Causality was never established, but development was discontinued. No clinical efficacy data for CJC-1295 was ever collected.
The compound that succeeded in the same indication using the same mechanism is tesamorelin: FDA-approved in 2010 with Phase 3 body composition data from 806 patients. CJC-1295 has a pharmacokinetic advantage (longer half-life, less frequent dosing) but zero clinical efficacy data. Tesamorelin has the efficacy data but requires daily injection. The pharmacokinetically superior compound never reached the clinical milestone.
Ipamorelin has the weakest clinical evidence of any GH secretagogue in the database. Its sole completed published human RCT was a Phase 2 trial for postoperative ileus (n=114, Beck et al. 2014, International Journal of Colorectal Disease). The primary endpoint was time to first tolerated meal after surgery. The result: 25.3 hours for ipamorelin versus 32.6 hours for placebo, P=0.15. Not statistically significant. Development was discontinued.
A second Phase 2 trial (NCT01280344, Helsinn Therapeutics) was completed in 2017. The results were never published. This is a meaningful gap, not a minor footnote.
Ipamorelin's one genuinely distinctive feature is ACTH/cortisol selectivity: it does not stimulate the stress hormone axis even at 200 times therapeutic doses. GHRP-2 and GHRP-6 both elevate cortisol and ACTH. Ipamorelin does not. For chronic use, this selectivity is a real safety advantage, and it is the primary scientific reason ipamorelin is preferred over older ghrelin mimetics.
Every other clinical application currently promoted for ipamorelin, including body composition, anti-aging, sleep quality, and muscle recovery, rests on mechanistic reasoning and GH biology extrapolation. No human RCT has tested any of these applications.
When you combine a compound whose development was terminated after a patient death with a compound whose only efficacy trial failed, the marketing has to do a lot of heavy lifting. And it does. "CJC-1295 + ipamorelin" is the single most commercially promoted peptide stack in the compounding industry.
The mechanistic rationale is sound. GHRHR activation (CJC-1295) and GHS-R1a activation (ipamorelin) converge on somatotroph GH release through independent intracellular pathways. The synergy in animal models is real and well-characterized. Each compound's individual GH-stimulating mechanism is confirmed in separate human trials.
What does not exist is a single human RCT demonstrating that the combination produces body composition improvements, sleep quality enhancement, anti-aging effects, or any other clinical outcome. The entire evidence base for the combination is: individually confirmed mechanisms plus animal model synergy data plus practitioner observation.
Tesamorelin is FDA-approved for the same core mechanism (GHRH receptor agonism producing GH elevation). It has Phase 3 data from 806 patients showing significant reduction in visceral adipose tissue. It requires daily injection and costs substantially more than research-grade CJC-1295. But it has something CJC-1295 does not: clinical proof that its GH elevation produces a measurable body composition outcome in humans.
Sermorelin was formerly FDA-approved (1990 diagnostic, 1997 pediatric) and has documented adult aging body composition data from the Khorram 1997 study (small but controlled), plus the Vitiello/Merriam cognitive function program. CJC-1295 has a longer half-life than sermorelin but less human clinical data than the compound it pharmacokinetically improves upon.
The CJC-1295 and ipamorelin combination is mechanistically rational, pharmacologically coherent, and clinically unvalidated. The GH synergy is real in animal models. The individual mechanisms work in humans. The clinical outcomes that people pay for, body composition, performance, anti-aging, sleep, have never been tested in a controlled human trial with either compound individually or in combination.
The most widely prescribed GH secretagogue protocol in compounding practice has never produced a single published data point showing it changes body composition, improves sleep, or slows aging in humans. The mechanism works. Whether the clinical outcomes follow is an open question, not a settled one.
Anyone using this combination is making a bet on mechanistic plausibility. That bet may turn out to be correct. But it has not been confirmed by the kind of evidence that distinguishes medicine from informed speculation.
Complete profiles with all use cases, dosing data, safety analysis, and editorial assessments: CJC-1295 and Ipamorelin (free profile). For context on the FDA-approved alternative: Tesamorelin. For the GHRP comparison: Sermorelin.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use